DoxorubicinCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsEtoposideAntineoplastic Agents, PhytogenicLomustineVinca AlkaloidsBleomycinVinblastineMethotrexateAntineoplastic AgentsTreatment OutcomeDrug ResistanceP-GlycoproteinDrug Administration ScheduleAntibodies, Monoclonal, Murine-DerivedCombined Modality TherapyLymphoma, Non-HodgkinPrednisoloneLeukemia P388AsparaginaseDaunorubicinDrug Resistance, MultipleLymphoma, Large B-Cell, DiffuseRemission InductionRhabdomyosarcomaDose-Response Relationship, DrugCytarabinePrecursor Cell Lymphoblastic Leukemia-LymphomaDexamethasoneHodgkin DiseaseIfosfamideMelphalanDisease-Free SurvivalVerapamilDactinomycinOligodendrogliomaSurvival AnalysisCisplatinDacarbazineDrug Resistance, NeoplasmCarcinoma, Small CellTime FactorsSurvival RateCatharanthusVindesineColchicineLeukemia, LymphoidTeniposideAntibiotics, AntineoplasticClinical Trials as TopicPodophyllotoxinChlorambucilMitoxantroneTumor Cells, CulturedDrug SynergismMultiple MyelomaSemustineFollow-Up StudiesDrug Screening Assays, AntitumorLeukemia L1210Sarcoma, EwingNeoplasm StagingWilms TumorKB CellsPeripheral Nervous System DiseasesCarmustineMultidrug Resistance-Associated ProteinsNimustineBrain NeoplasmsPrognosisDrug-Related Side Effects and Adverse ReactionsLiposomesLymphoma, FollicularDrug EvaluationCell SurvivalProspective StudiesDrug CarriersPaclitaxelRecurrenceLymphomaInfusions, IntravenousLymphoma, B-CellLung NeoplasmsRandom AllocationAdministration, OralInjections, IntravenousMedulloblastomaCell Line, TumorAntibodies, Monoclonal6-MercaptopurineMesnaThrombocytopeniaNauseaAntimitotic AgentsNeoplasm Recurrence, LocalMicrotubulesDouble-Blind MethodNeuroblastomaTubulin